

**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Kimme Hyrich  
Rik Lories  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)

**Disclaimer:** The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

**Copyright:** © 2021 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

*ARD* is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases*, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

**Editorial**

- 547** Vitamin K and osteoarthritis: is there a link?  
*R F Loeser, F Berenbaum, M Kloppenburg*

**Review**

- 550** Anti-inflammatory therapy for COVID-19 infection: the case for colchicine  
*A Z Reyes, K A Hu, J Teperman, T L Wampler Muskardin, J-C Tardif, B Shah, M H Pillinger*

**Rheumatoid arthritis**

- 558** Large-scale meta-analysis across East Asian and European populations updated genetic architecture and variant-driven biology of rheumatoid arthritis, identifying 11 novel susceptibility loci  
*E Ha, S-C Bae, K Kim*
- 566** Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis  
*J F Baker, B R England, M George, G Cannon, B Sauer, A Ogdie, B C Hamilton, C Hunter, M J Duryee, G Thiele, T R Mikuls*
- 573** *Streptococcus* species enriched in the oral cavity of patients with RA are a source of peptidoglycan-polysaccharide polymers that can induce arthritis in mice  
*R Moentadj, Y Wang, K Bowerman, L Rehaume, H Nel, P O Cuiv, J Stephens, A Baharom, M Maradana, V Lakeis, M Morrison, T Wells, P Hugenholtz, H Benham, K-A Le Cao, R Thomas*

**Psoriatic arthritis**

- 582** Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial  
*X Baraliakos, L Gossec, E Pournara, S Jeka, A Mera-Varela, S D'Angelo, B Schulz, M Rissler, K Nagar, C Perella, L C Coates*
- 591** IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors  
*A Nerviani, M-A Boutet, W S G Tan, K Goldmann, N Purkayastha, T A Lajtos, R Hands, M Lewis, S Kelly, C Pitzalis*

**Osteoarthritis**

- 598** Vitamin K antagonist anticoagulant usage is associated with increased incidence and progression of osteoarthritis  
*C G Boer, I Szilagyi, N L Nguyen, T Neogi, I Meulenbelt, M A Ikram, A G Uitterlinden, S Bierma-Zeinstra, B H Stricker, J B van Meurs*
- 605** Warfarin use and risk of knee and hip replacements  
*P Ballal, C Peloquin, C G Boer, T Neogi*

**Paediatric rheumatology**

- 610** Geospatial clustering of childhood IgA vasculitis and IgA vasculitis-associated nephritis  
*M Sapina, M Frkovic, M Sestan, S Srsen, A Ovuka, M Batnozc Varga, K Kramaric, D Brdaric, K Milas, A Gagro, M Jelusic*
- 617** Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN- $\gamma$  hyper-responsiveness and risk for macrophage activation syndrome  
*G S Schuler, A V Pickering, T Do, S Dhakal, N Fall, D Schnell, M Medvedovic, N Salomonis, S Thornton, A A Grom*
- 626** Association of novel rare coding variants with juvenile idiopathic arthritis  
*X Meng, X Hou, P Wang, J T Glessner, H-Q Qu, M E March, S Zhang, X Qi, C Zhu, K Nguyen, X Gao, X Li, Y Liu, W Zhou, S Zhang, J Li, Y Sun, J Yang, P M A Sleiman, Q Xia, H Hakonarson, J Li*

**MORE CONTENTS ►**

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

## Systemic lupus erythematosus

- 632** Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus



*X Yin, K Kim, H Suetsugu, S-Y Bang, L Wen, M Koido, E Ha, L Liu, Y Sakamoto, S Jo, R-X Leng, N Otomo, V Laurylenka, Y-C Kwon, Y Sheng, N Sugano, M Y Hwang, W Li, M Mukai, K Yoon, M Cai, K Ishigaki, W T Chung, H Huang, D Takahashi, S-S Lee, M Wang, K Karino, S-C Shim, X Zheng, T Miyamura, Y M Kang, D Ye, J Nakamura, C-H Suh, Y Tang, G Motomura, Y-B Park, H Ding, T Kuroda, J-Y Choe, C Li, H Niuro, Y Park, C Shen, T Miyamoto, G-Y Ahn, W Fei, T Takeuchi, J-M Shin, K Li, Y Kawaguchi, Y-K Lee, Y Wang, K Amano, D J Park, W Yang, Y Tada, K Yamaji, M Shimizu, T Atsumi, A Suzuki, T Sumida, Y Okada, K Matsuda, K Matsuo, Y Kochi, Japanese Research Committee on Idiopathic Osteonecrosis of the Femoral Head, L C Kottyan, M T Weirauch, S Parameswaran, S Eswar, H Salim, X Chen, K Yamamoto, J B Harley, K Ohmura, T-H Kim, S Yang, T Yamamoto, B-J Kim, N Shen, S Ikegawa, H-S Lee, X Zhang, C Terao, Y Cui, S-C Bae*

## Systemic sclerosis

- 641** New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis

*D Khanna, S Huang, C J F Lin, C Spino*

- 651** Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling



*N Kajio, M Takeshita, K Suzuki, Y Kaneda, H Yamane, K Ikeura, H Sato, S Kato, H Shimizu, K Tsunoda, T Takeuchi*

## Epidemiology

- 660** Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic

*N Serling-Boyd, K M D'Silva, T Y T Hsu, R Walkwork, X Fu, E M Gravallese, A M Jorge, Y Zhang, H Choi, J A Sparks, Z S Wallace*

## Letters

- 668** Realising early recognition of arthritis in times of increased telemedicine: the value of patient-reported swollen joints



*C Rogier, B T van Dijk, E Brouwer, P H P de Jong, A H M van der Helm-van Mil*

- 669** What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern



*P Gauckler, E L Bettac, M Nairz, C Dufiner, A K Luger, M Stein, D Wanner, B C Böckle, M Tiefenthaler, P Schratzberger, H Neuwirt, L Harasser, G Mayer, A Kronbichler*

- 671** Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland

*A H Bjornsson, G Grondal, M Kristjansson, T Jonsdottir, T J Love, B Gudbjornsson, ICEBIO*

- 672** Declining in-hospital mortality gap between systemic lupus erythematosus (SLE) and non-SLE hospitalisations: a national study

*J A Singh, J D Cleveland*

- 675** The virtual fishbowl: bringing back dynamic debates to medical conferences

*F Muehlensiepen, J Mucke, M Krusche, S Kurkowski, G Bendzuck, I Koetter, V Lemarié, M Grammer, M Heinze, H Schulze-Koops, J Knitza*

## Electronic pages

- e62** COVID-19 in patients with rheumatological diseases treated with anti-TNF

*C A Brito, J G Paiva, F N Pimentel, R S Guimarães, M R Moreira*

- e63** Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences

*J Zhao, R Pang, J Wu, Y Guo, Y Yang, L Zhang, X Xia*

- e64** Response to: 'COVID-19 in patients with rheumatological diseases treated with Anti-TNF' by Brito *et al* and 'Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences' by Zhao *et al*

*K M D'Silva, N Serling-Boyd, R Walkwork, T Hsu, J A Sparks, Z S Wallace*

- e65** Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic

*P Santos-Moreno, J Chavez-Chavez, S M Hernández-Zambrano, D P Rivera-Triana, R A Castiblanco-Montañez, A Aza, D Buitrago-García, L Villarreal, A Rojas-Villarraga*

- e66** Response to: 'Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic' by Santos-Moreno *et al*  
*E Bozzalla Cassione, G Zanframundo, A Biglia, V Codullo, C Montecucco, L Cavagna*
- e67** Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab  
*H Schulze-Koops, K Krueger, I Vallbracht, R Hasseli, A Skapenko*
- e68** Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops *et al*  
*S Monti, C Montecucco*
- e69** COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine  
*C L Teh, Y K Cheong, W R Wan Musa, S A Wan Mohd Akbar, N Mat Husin, S C Gun*
- e70** Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh *et al*  
*A Mathian, Z Amoura*
- e71** Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India  
*M Goyal, P Patil, H Pathak, S Santhanam, A Goel, V Sharma, A Pandey, N Gupta, R Jain, S Akerkar, P Das, R Dudam, N Mendiratta, B D Pandey, M CB, B K Singh, S Kumar, N Nolleha, S Jain, S Jain, A Sharma, D P Misra*
- e72** Response to: 'Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India' by Goyal *et al*  
*A Mathian, Z Amoura*
- e73** Presence of antiphospholipid antibodies in COVID-19: a case series study  
*L M Amezcua-Guerra, G Rojas-Velasco, M Brianza-Padilla, A Vázquez-Rangel, R Márquez-Velasco, F Baranda-Tovar, R Springall, H González-Pacheco, Y Juárez-Vicuña, C Tavera-Alonso, F Sanchez-Muñoz, M Hernández-Salas*
- e74** Response to: 'Presence of anti-phospholipid antibodies in COVID-19: a case series study' by Amezcua-Guerra *et al*  
*A Mathian, M Pineton De Chambrun, A Combes, Z Amoura*
- e75** Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients  
*E G Favalli, O De Lucia, M Biggioggero, N Del Papa, R Caporali*
- e76** Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli *et al*  
*V C Romão, A R Cruz-Machado, J E Fonseca*
- e77** Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus  
*Y Kondo, Y Kaneko, T Oshige, H Fukui, S Saito, M Okayama, H Kamata, M Ishii, N Hasegawa, K Fukunaga, T Takeuchi*
- e78** Response to: 'Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus' by Kondo *et al*  
*A Mathian, Z Amoura*
- e79** Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'  
*F Messina, F Pampaloni, S Piaserico*
- e80** Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina *et al*  
*P-M Duret, L Spielmann, L Messer*
- e81** Correction: *Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome*
- e82** Correction: *Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial*
- e83** Correction: *Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme*
- e84** Correction: *Methotrexate and BAFF interaction prevents immunization against TNF inhibitors*